Clinical Trial 38012

Los Angeles, CA 90017

Study Summary:

Clinical research study to find out if the drug dabrafenib is safe and to determine how dabrafenib is metabolized (broken down in the body) by people who have varying degrees of liver impairment (a condition in which the liver is not working as well as it normally should) compared with people who do not have liver (hepatic) impairment.

phase I study

You will check into the study clinic on Day -1 and You will remain at the study clinic for 6 days continuously starting from the day before you take the study drug (Day -1 to Day 5).

Inclusion Criteria:

Male and/or female subjects 18-75 years of age on the day of Informed Consent signature.

Body mass index (BMI) between ≥18.0 and ≤38.0 kg/m2, with body weight ≥ 110 lbs and no more than 300 lbs

Confirmed hepatic disease by at least one of the following criteria:
- Histologically by prior liver biopsy showing cirrhosis.
- Clinically by physical examination (e.g., liver firmness to palpation, splenic
enlargement, spider angioma, palmar erythema, parotid hypertrophy, testicular
atrophy, ascites, presence of asterixis or gynecomastia).

Qualified Participants May Receive:

You will receive up to $2,200.00 if you complete the entire study.

View Contact Phone Number

Research Site Profile

View Clinic Profile

Study is Available At:

American Institute of Research
1127 Wilshire Blvd Suite 300
Los Angeles, CA 90017
View Clinic Location


If you would like to be contacted by the clinical trial representative and live within 50 miles of this clinic, please enter your contact information, then click 'I Am Interested In This Study'